This study is to investigate the genomic methylation in cervical adenocarcinoma in Xinjiang, China, using the DNA methylation analysis chips.
Introduction
With the wide application of cervical thin-layer cytology in cervical cancer screening, the incidence of cervical squamous cell cancer is declining, but the incidence of cervical adenocarcinoma is rising. [1] [2] [3] [4] It has been shown that the detection rate of cervical cancer increased from 5% to 10%-20% and showed a trend to occur in younger people in the past 40 years. [5] Cervical adenocarcinoma originates from the cervical canal. [6] The early diagnosis of cervical adenocarcinoma is difficult due to its endogenous growth. [7] The disease is more common in young women. [8] The main clinical manifestations are the vaginal bleeding and vaginal discharge, most of which are nonspecific cases. [9] Therefore, the study about the pathogenesis of cervical adenocarcinoma is particularly urgent.
Most scholars believe that cervical adenocarcinoma is related with the human papilloma virus (HPV) infection and estrogen. [10, 11] De Sanjose has summarized the data from 10,575 cases of cervical cancer HPV infection in 38 countries, including the North America, Central America, Europe, Asia, Africa, and Oceania. [12] The HPV positive rate in 951 cases of cervical adenocarcinoma is 65.7%. [12] Thus, the occurrence and development of cervical adenocarcinoma still need further study.
DNA methylation is an important part of epigenetics and regulation of genomic function. [13] Some papers have studied the mechanism and methylation of cervical adenocarcinoma, [14, 15] but they only focused on one or a few genes. [16] In this study, the genomic methylation of cervical adenocarcinoma was analyzed using the Illumina 850K methylation chip. The specific genes and their potential targets were analyzed by the bioinformatic analysis. Our findings may provide the basis for the further study of the molecular mechanism of cervical adenocarcinoma.
Materials and methods

Clinical data
Patients with cervical adenocarcinoma (n = 5) hospitalized at Affiliated Tumor Hospital of Xinjiang Medical University from January 2016 to June 2017 were enrolled in this study. Their age ranged from 42 to 60 years old, with the median age of 44 years old. They were treated with laparoscopic surgery or laparotomy, and adenocarcinoma tissues were collected during surgery. Inclusion criteria: patients with cervical adenocarcinoma confirmed by pathology; patients not receiving chemotherapy, radiotherapy, or hormone treatment, prior to surgery; and patients without other malignancies or severe medical conditions. Exclusion criteria: patients pathologically diagnosed as nonprimary cervical adenocarcinoma; the specimens failing to meet the experimental requirements; and carcinoma merged with other tumors. For the control, normal cervical tissues were collected from 5 patients who were hospitalized during the same period and received hysterectomy due to noncervical lesions of other gynecologic benign diseases. The control patients matched with the cervical adenocarcinoma patients in terms of geography, age, educational level, economic income, and body mass index. All patients and their families signed the informed consent form. The study was approved by the ethics review board of the Affiliated Tumor Hospital of Xinjiang Medical University.
Detection of methylation by chip
Genome-wide methylation was detected by the Illumina Human Methylation 850K Beadchip (Zhuoli Tech, Shanghai, China). Briefly, the genomic DNA was extracted using QIAamp DNA MiniKit (Qiagen, Hilden, Germany) and treated with bisulfite to convert cytosine to uracil. MSA4 was produced by alkali denaturation and genomic amplification. Probes were designed for the converted sequence and hybridized with the chip. The methylation status was determined by calculating the ratio of fluorescent signals.
Bioinformatic analysis
The differentially expressed genes were annotated with gene ontology (GO) and analyzed through KEGG database. The GO annotation analysis included the biologic process, cellular component, and molecular function, which was performed with the DAVID database. P .05, which was given directly in the database, was used as the significance threshold to screen the results and to verify the P-value.
Statistical analysis
Data were processed using the SPSS 19.0 statistical software. Independent sample t test was used for comparison. The results of Illumina methylation chip were analyzed by the GenomeStudio software (Illumina, San Diego, CA). The methylation level of each site was calculated. Difference scores >13 or <À13, with Db > 0.2 or <À0.2, were used as cut-off points to screen the differential methylation sites. The similarity between the samples was analyzed by the principal component analysis (PCA) after beta value standardization through the dimensionality reduction method. The major signaling pathways by KEGG were selected according to the criteria of P < .05 and false discovery rate (FDR) < 0.05.
Results
Genome-wide detection of methylation in the cervical adenocarcinoma tissue by the methylation chip
The data from cervical adenocarcinoma and normal cervical tissue samples were preprocessed and normalized. Two-dimensional PCA analysis results were obtained and shown in Figure 1 . Different colors indicate different samples. The closer the distance between samples was, the closer the expression pattern of sample gene was. Thus, the gene methylation profile of cervical The 850K methylation sites in the cervical and normal adenocarcinoma tissues were analyzed using the Illumina 850K methylation chip. We found that 4056 sites showed differential expression in cervical adenocarcinoma tissues compared to normal cervical tissues, of which 3738 were hypermethylated and 318 were hypomethylated (Fig. 2) . The different methylation sites in cervical adenocarcinoma were widely distributed, from chromosome 1 to the chromosome 22 (Fig. 3) . Among them, chromosome 1 and chromosome 2 contained the largest number of methylation sites (418 and 271, respectively), while chromosome 21 and chromosome 18 contained the least number of methylation sites (21 and 42, respectively).
Gene ontology functional analysis
The GO functional annotation analysis of the differentially expressed methylation sites showed that these genes were mainly enriched in cellular processes, histomorphology, nervous system development, and biologic processes (Fig. 4) . The results of cell component analysis showed that molecules distributed in the cytoplasm, cell protrusions, neurons, and intracellular components were significantly enriched. At the molecular level, functional annotation showed that the highly enriched genes were related with sequence-specific DNA binding, phosphotransferase, protein kinase, and anion transmembrane transport.
KEGG signaling pathway analysis
We further studied the signal pathways using the KEGG database. According to the criteria of P < .05 and FDR < 0.05, the most prominent 20 major signaling pathways were selected (Fig. 5) . Furthermore, the 3000 methylation variable position genes with the most significant difference were further analyzed by KEGG. A total of 210 genes were screened from 10 pathways. The 210 genes were analyzed for inter-gene interaction, and 8 pathways were found to be matched best, including the neuroactive ligand-receptor interaction, calcium signaling pathway, focal adhesion, pathways in cancer, regulation of actin cytoskeleton, MAPK signaling pathway, Wnt signaling pathway, and tight junction. The most significant signal pathway was the neuroactive ligand-receptor interaction. Additionally, the Gene-net-work analysis showed that the genes of CCND1, CTNNB1, MAPK10, and PRKCA were involved in multiple pathways (Fig. 6) , indicating their possible roles in cervical adenocarcinoma development. 
Discussion
Genome-wide methylation is one of the most well-studied mechanisms in the field of epigenetics, which is closely related to the occurrence and development of diseases, including the cervical cancer. Jha et al found that the tumor suppressor genes p53 and p73 showed higher methylation degree in cervical cancer samples compared with normal samples. [17] Additionally, previous methylation analysis of 7 genes by QMSPCR showed that the detection sensitivities of SOX1, PAX1, ZNF582, PTPRR, AJAP1, HS3ST2, and POU4F3 were 100%, 86%, 71%, 86%, 86%, 57%, and 100%, respectively; and the specificities were 67%, 79%, 85%, 50%, 52%, 96%, and 52%, respectively. [18] Our study showed that 4056 sites showed differential expressions in cervical adenocarcinoma tissues compared to normal cervical tissues, of which 3738 were hypermethylated and 318 were hypomethylated. The different methylation sites in cervical adenocarcinoma were widely distributed, from chromosome 1 to chromosome 22. These results indicate that the methylation sites in cervical adenocarcinoma are widely distributed. The numbers and distribution of these sites in different chromosomes vary greatly.
We also analyzed these differentially expressed genes through the GO functional annotation. We found that differentially methylated genes in cervical adenocarcinoma were mainly involved in tumor growth, development, metabolism, ion transport, transcriptional regulation, cell division, cell cycle regulation, and signal transduction process. Many studies have shown that methylation is involved in the development of cervical cancer. For instance, several methylation genes like CDH1, CDKN2A, Rb1, and TP53 are involved in ion transport, cell cycle regulation, tumor growth, and metabolism in cervical cancer. [19] However, methylation of the p16 gene may play an important role in the carcinogenesis of cervical cancer in cooperation with HPV infection. [20] It has been shown that the hypermethylation of genes can affect a variety of cellular pathways, such as DNA repair (mismatch repair gene and O6-methylguanine-DNA methyltransferase), apoptosis-related protein kinase (DAPK), apoptosis-activating factor, and cell cycle (p14 gene). [21] [22] [23] [24] [25] Pathway analysis in this study showed that differentially methylated genes were mainly involved in tumorigenesis, apoptosis, immune, and signal transduction. Among these pathways, the most significant one was the neural active ligand-receptor interaction pathway (neuroactive ligand-receptor interaction), which is a collection of all receptors and ligands on the plasma membrane associated with intracellular and extracellular signaling pathways. [26] Further cluster analysis found that the differentially methylated genes covered a variety of different functional communities, indicating that there are many types of genes involved in regulation of the occurrence and development of cervical adenocarcinoma. Jha et al have found some driving genes highly relevant to cervical adenocarcinoma, using the next-generation sequencing technologies, including ND5, TG, AGXT, MYH7, FGA, APOC3, APOA1, C3, APCS, FBF1, SERPINA1, S100A9, and TXNIP GC. [27] More studies have shown that PAX1, SOX1, EPB41L3, ARHGAP6, HAND2, Lhx9 Hey2, NKX2-2, PCDH10, PITX2, Prox1, Tbx3, IKBKG, rab6c, and DAPK1 could be used as screening biomarkers for cervical cancer diagnosis. [28] [29] [30] Moreover, our Gene-net-work analysis showed that methylation-deficient genes such as CCND1, CTNNB1, MAPK10, and PRKCA were involved in multiple cervical adenocarcinoma-related pathways and may also serve as candidate molecular markers of cervical adenocarcinoma, which however needs more study.
In conclusion, we used the illumina Human Methylation 850K Beadchip methylation chip to detect the methylation sites in cervical adenocarcinoma and normal cervical tissues. Our findings show that the methylation modification in cervical adenocarcinoma cells is abnormal. The hypermethylation sites occur more frequently and are mainly enriched in functional categories such as the tumor growth, development, and metabolism. The most abundant signaling pathway is the signal pathway of neuroactive ligand-receptor interaction, indicating that the abnormal methylation may be involved in the development of cervical adenocarcinoma. Our work is only one of the beginning studies of genomic methylation in cervical adenocarcinoma. We need more comprehensive and more accurate results, and also need to expand the sample size for further analysis and verification. These could be very helpful for the early diagnosis, treatment, and prognosis of cervical adenocarcinoma, and for the development of targeted drugs.
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